Drug and alcohol dependence最新文献

{"title":"Is cannabis legalization associated with treatment completion? A study of pregnant women admitted for cannabis use in substance use treatment facilities, 2020–2022","authors":"Rogie Royce Carandang ,&nbsp;Taeho Greg Rhee ,&nbsp;Toan Ha ,&nbsp;Shayna D. Cunningham","doi":"10.1016/j.drugalcdep.2026.113023","DOIUrl":"10.1016/j.drugalcdep.2026.113023","url":null,"abstract":"<div><h3>Background</h3><div>Cannabis is the most used illicit substance during pregnancy in the United States. While cannabis legislation is associated with prevalence and access to care, its relationship with treatment completion among pregnant women is unclear. This study examined the association between cannabis legalization and treatment completion among pregnant women admitted for cannabis use from 2020 to 2022.</div></div><div><h3>Methods</h3><div>This retrospective cross-sectional analysis used data from the Treatment Episode Data Set-Discharge (TEDS-D) to analyze treatment completion among pregnant women aged 12 or older who were admitted for cannabis use (n = 13,088) across states with fully legalized, partially legalized (medical use only), or illegal cannabis policies. Multivariable-adjusted logistic regression was used to assess the association between legalization status and treatment completion, with subgroup analyses by treatment setting and referral source.</div></div><div><h3>Results</h3><div>Among pregnant women admitted for cannabis use, 28.3 % completed treatment. Compared to states where cannabis remained illegal, those in states with fully legalized cannabis had significantly lower odds of treatment completion (adjusted odds ratio [AOR], 0.33 [95 % confidence interval, 0.27–0.41]), with a similar trend in states with partial legalization (AOR, 0.33 [0.28–0.40]). The negative association between cannabis legislation and treatment completion was more pronounced in outpatient settings than in residential programs, and stronger among court/other referrals than among voluntary referrals.</div></div><div><h3>Conclusions</h3><div>Cannabis legalization may be negatively associated with treatment completion among pregnant women admitted for cannabis use. Further research is needed to identify policy-related barriers and develop evidence-based interventions that improve treatment engagement and retention in this vulnerable population.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113023"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Not in my backyard”: The impact of recovery residences on property values","authors":"Ryan Ramphul ,&nbsp;Sheryl A. McCurdy ,&nbsp;Jooyeon Lee ,&nbsp;Yanchen Liu ,&nbsp;Yixiao Chen ,&nbsp;Serena A. Rodriguez ,&nbsp;Kathryn R. Gallardo ,&nbsp;Sreelatha Akkala ,&nbsp;Hadiza Theyra-Enias ,&nbsp;J. Michael Wilkerson","doi":"10.1016/j.drugalcdep.2026.113044","DOIUrl":"10.1016/j.drugalcdep.2026.113044","url":null,"abstract":"<div><h3>Background</h3><div>In 2023, an estimated 39.6 million adults aged ≥ 18 years had a substance use disorder (SUD) and 94.7 % did not seek treatment. Recovery residences provide essential support for individuals recovering from SUD, yet their presence in residential neighborhoods often raises concerns on potential decline in property values. Our study examines the relationship between presence of recovery residences and median home values at the census tract level in Texas.</div></div><div><h3>Methods</h3><div>We used publicly available tract-level data on area, total population, housing units, CDC/ATSDR Social Vulnerability Index (SVI), and median home values. Data on the recovery residences were obtained from a cross-sectional statewide survey of substance use service providers. Census tracts with and without recovery residences were matched using a k-nearest neighbors (KNN) algorithm. Logistic regression and permutation tests were used to assess differences in median home values between matched tracts.</div></div><div><h3>Results</h3><div>Results from comparison of 329 census tracts with recovery residences and 1161 matched controls showed no significant association between presence of recovery house and property values, after adjusting for population and the covariates that are used for KNN matching. Sensitivity analysis showed no significant association between median home value and the presence of recovery housing.</div></div><div><h3>Conclusions</h3><div>Our findings suggest no significant association between the likelihood of a tract having recovery residence and home values. Policymakers should consider these findings when addressing zoning restrictions and community opposition to recovery housing.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113044"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146034997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Test-retest reliability of mgTHC consumption in the self-administered Cannabis Exposure Index (CEI)","authors":"Deborah S. Hasin ,&nbsp;Jacob Borodovsky ,&nbsp;Melanie Wall ,&nbsp;Mohammad I. Habib ,&nbsp;Eilis Murphy ,&nbsp;Jun Liu ,&nbsp;Malki Stohl ,&nbsp;Cara A. Struble ,&nbsp;Ofir Livne ,&nbsp;Eliana Greenstein ,&nbsp;Efrat Aharonovich ,&nbsp;Caroline G. Wisell ,&nbsp;Alan J. Budney","doi":"10.1016/j.drugalcdep.2026.113028","DOIUrl":"10.1016/j.drugalcdep.2026.113028","url":null,"abstract":"<div><h3>Introduction</h3><div>Cannabis legalization and adult use are expanding across the U.S., requiring greater knowledge of cannabis risks and benefits. Cannabis use measures traditionally assessed frequency but omitted quantity, an essential element of consumption that is complicated by increasingly varied cannabis products and use patterns. To address this, we developed the self-administered CEI (Cannabis Exposure Inventory) to determine milligrams of THC used per using day (mgTHC/using day). In this study, we examined the test-retest reliability of the CEI mgTHC measure and key component items (i.e., products, routes of administration).</div></div><div><h3>Methods</h3><div>Participants were recruited through social media (Facebook and Instagram ads) and Qualtrics Research panels. Eligible participants (n = 511) completed initial and retest CEI surveys. Chance-corrected agreement between initial and retest surveys on mean mgTHC/using day was indicated with Intraclass Correlation Coefficients (ICCs); kappa (k) indicated reliability of key dichotomous component variables.</div></div><div><h3>Results</h3><div>Overall, ICC for mean mgTHC/using day= 0.77, indicating substantial reliability. In demographic subgroups, ICCs were 0.54 (‘other’ race/ethnicity) to 0.86 (Hispanic). ICCs for mean mgTHC/using day among those who used for medical-only, recreational-only and medical-plus-recreational reasons were 0.72, 0.69 and 0.77, respectively; ICCs for those in non-legalized, medical-only and medical-plus-recreational states were 0.70, 0.92 and 0.75, respectively. Binary measures generally exhibited substantial reliability (mean k, last 30 days=0.74; last 7 days=0.73).</div></div><div><h3>Conclusion</h3><div>Findings support the CEI mgTHC measure as a reliable instrument for quantifying cannabis use, addressing a critical gap in cannabis measurement. This measure offers a promising approach to provide urgently-needed information on potential harms and benefits of THC exposure.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113028"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145974310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dyadic association between support persons’ attitudes towards medication for opioid use disorder and patients’ mental health outcomes","authors":"Kyle J. Moon ,&nbsp;Lane F. Burgette ,&nbsp;Jasmin Choi ,&nbsp;Katherine Nameth ,&nbsp;Kevan Shah ,&nbsp;Katherine E. Watkins ,&nbsp;Karen Chan Osilla","doi":"10.1016/j.drugalcdep.2026.113053","DOIUrl":"10.1016/j.drugalcdep.2026.113053","url":null,"abstract":"<div><h3>Introduction</h3><div>Nearly one in three adults with opioid use disorder (OUD) has co-occurring depression or anxiety. Pervasive stigma towards medication for OUD has been identified as a barrier to OUD treatment initiation and retention, but whether stigma also complicates patient mental health outcomes remains unclear.</div></div><div><h3>Methods</h3><div>We analyzed longitudinal, dyadic data (n = 356 dyads) from a cohort of patients receiving buprenorphine from community health centers in California, who were accompanied by support persons (e.g., partner, family member, friend). We assessed how changes in support persons’ stigmatizing attitudes towards buprenorphine were associated with patients’ depressive and anxiety symptoms at 3-month follow-up using ordinary least squares regression models. To aid in clinical interpretability, we used logistic regression models to estimate the probability of clinically significant depressive and anxiety symptoms at 3-month follow-up.</div></div><div><h3>Results</h3><div>Support persons’ changes in stigmatizing attitudes towards buprenorphine were significantly associated with patients’ depressive (χ²= 10.95, <em>P</em> = 0.012) and anxiety (χ² = 14.40, <em>P</em> = 0.002) symptoms at follow-up, adjusted for patients’ sociodemographic characteristics and baseline symptoms. Patients whose support person reported increased stigma towards buprenorphine had the highest estimated probability of clinically significant depressive (36.7 % [95 % CI: 21.2, 52.1]) and anxiety symptoms (33.3 % [95 % CI: 18.7, 47.9]).</div></div><div><h3>Conclusions</h3><div>Stigmatizing attitudes towards buprenorphine held by patients’ loved ones were associated with worse depression and anxiety outcomes. Interventions are needed to address the stigma towards MOUD among support persons; these interventions may also improve the mental health and wellbeing of patients with OUD.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113053"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146035052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging a digital health intervention to improve recovery outcomes among people with substance misuse experiencing housing insecurity","authors":"Vidya Eswaran ,&nbsp;Fanghong Dong ,&nbsp;Xiao Li ,&nbsp;Hannah S. Szlyk ,&nbsp;Nathaniel A. Dell ,&nbsp;Erin Kasson ,&nbsp;Jessica Williams ,&nbsp;Patricia A. Cavazos-Rehg","doi":"10.1016/j.drugalcdep.2026.113022","DOIUrl":"10.1016/j.drugalcdep.2026.113022","url":null,"abstract":"<div><h3>Background</h3><div>People with substance use disorders (PwSUD) who experience housing insecurity have disproportionate overdose deaths. Digital interventions may improve care among PwSUD, but evidence specifically for housing-insecure PwSUD, who face unique barriers, remains limited.</div></div><div><h3>Methods</h3><div>We examined the efficacy of a mHealth tool (<em>uMAT-R</em>) among people who have misused substances and reported current housing insecurity. Substance use, cravings, access to basic needs, social disconnection, and digital literacy were assessed at baseline and 1 month and compared by <em>uMAT-R</em> use<em>.</em> Generalized estimating equations were employed to assess the efficacy of the intervention.</div></div><div><h3>Results</h3><div>Participants who logged into <em>uMAT-R</em> were less likely to report other non-opioid illicit drug use (aOR (95 %CI): 0.49(0.29, 0.85)). Similarly, those who messaged the e-coach were less likely to report using opioids (aOR(95 %CI): 0.39(0.21, 0.73)) or other illicit drugs (aOR (95 % CI): 0.53(0.30, 0.92)) during past 30-days. Significant interaction effects were found in <em>uMAT-R</em> use by time in cravings (Coef (95 %CI): −2.11(-4.07, −0.17)) and perceived burdensomeness (Coef(95 %CI): −2.62 (-4.91, −0.36)). Messaging an e-coach by time was significantly associated with improved health literacy (Coef (95 %CI): 0.61(0.05, 1.18)) and decreased thwarted belongingness (Coef(95 %CI): −0.36 (-0.71, −0.02).</div></div><div><h3>Conclusion</h3><div>Our preliminary findings suggest that people who have misused substances and experience housing insecurity may benefit from uMAT-R, which was associated with improved recovery outcomes. Future research is needed to examine the unique barriers experienced by this population and how mHealth tools can be used to provide tailored, equitable access to supportive resources to reduce barriers and promote long-term recovery.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113022"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developmental windows of vulnerability: Substance-specific effects of prenatal exposure timing on child psychopathology","authors":"Qiaojun Li ,&nbsp;Zhen Pang ,&nbsp;Yansong Lu ,&nbsp;Lu Jiang ,&nbsp;Mengyao Sun ,&nbsp;Jiayuan Xu","doi":"10.1016/j.drugalcdep.2026.113029","DOIUrl":"10.1016/j.drugalcdep.2026.113029","url":null,"abstract":"<div><h3>Background</h3><div>Prenatal alcohol, tobacco, and cannabis exposure are known risks for childhood psychopathology symptoms, but gaps persist in identifying substance-specific developmental vulnerability windows. Exposure timing relative to maternal pregnancy awareness may alter outcomes, yet this temporal specificity remains unclarified, limiting targeted risk assessment and prevention.</div></div><div><h3>Methods</h3><div>Data from 7777 children in the Adolescent Brain Cognitive Development Study (enrolled 2016–2018) were analyzed. Prenatal substance exposure timing was categorized as pre-awareness (exposure before maternal awareness of pregnancy) and post-awareness (exposure after maternal awareness of pregnancy). Six domains of childhood psychopathology symptoms were assessed via the Child Behavior Checklist (CBCL). Linear mixed-effects models were applied to investigate the timing effects of prenatal substance exposure on childhood psychopathology symptoms, adjusting for covariates.</div></div><div><h3>Results</h3><div>The analysis revealed distinct temporal patterns of risk for each substance. Childhood psychopathology symptoms were specifically linked to pre-awareness exposure for alcohol and post-awareness exposure for cannabis. In contrast, post-awareness alcohol use and pre-awareness cannabis use showed no significant associations. Prenatal tobacco exposure conferred modest risks across all timings without temporal divergence.</div></div><div><h3>Conclusions</h3><div>Prenatal substance exposure has substance-specific, timing-dependent effects on childhood psychopathology relative to maternal pregnancy awareness. Findings support distinct developmental vulnerability windows, highlighting the need to include substance type and timing in public health guidelines and clinical risk stratification.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113029"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145923354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gabapentin utilization and nontherapeutic use relative to select comparator drugs, United States 2013–2022","authors":"Sara Karami ,&nbsp;Jae Wook Yoo,&nbsp;Corinne Woods,&nbsp;Saranrat Wittayanukorn Conrad,&nbsp;Jana McAninch,&nbsp;Tamra Meyer,&nbsp;Celeste Mallama","doi":"10.1016/j.drugalcdep.2026.113026","DOIUrl":"10.1016/j.drugalcdep.2026.113026","url":null,"abstract":"<div><h3>Background</h3><div>Gabapentin prescribing has increased over the past decade, including as part of efforts to reduce opioid analgesic use. Data on trends and scope of harms from gabapentin nontherapeutic use (NTU) are needed.</div></div><div><h3>Methods</h3><div>For gabapentin and selected contextual comparator drugs (pregabalin, diazepam, oxycodone), we describe utilization using a dispensed prescriptions all-payer claims database (2013–2023) and adverse events for NTU exposure cases using Poison Center data (2013–2022). We then calculated utilization-adjusted NTU exposure case rates, based on prescription units dispensed, for each drug.</div></div><div><h3>Results</h3><div>From 2013–2023, the number of units (e.g., tablets) dispensed increased for gabapentin (4.4–7.7 billion [B]) and pregabalin (0.68–1.0B) and decreased for diazepam (0.7–0.3B) and oxycodone (4.2–2.5B). From 2013–2022, gabapentin NTU exposure cases (N = 8729) exceeded pregabalin (N = 1257) and diazepam (N = 2452) but not oxycodone (N = 17,808) NTU exposure cases. Gabapentin NTU exposure cases and utilization-adjusted NTU exposure case rates increased from 2013-2017, then decreased through 2022; trends were similar for pregabalin, decreased throughout for diazepam, and fluctuated for oxycodone. From 2013–2022, gabapentin annual utilization-adjusted NTU exposure case rates most closely resembled those of pregabalin (range: 0.09–0.16 versus 0.08–0.22 exposure cases per million units dispensed), while diazepam and oxycodone exhibited higher rates (range: 0.33–0.55 and 0.39–0.85 exposure cases per million units dispensed, respectively). Most gabapentin (68 %) and comparator (55–80 %) NTU exposure cases involved multiple substances, particularly opioids, resulting in more severe clinical outcomes than single-substance exposures.</div></div><div><h3>Conclusions</h3><div>Our study highlights the harms from gabapentin NTU, particularly in combination with opioids.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113026"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145974308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inequities in blunt use across multiple socio-demographic intersections among US adults","authors":"Allison M. Glasser ,&nbsp;Jessica K. Jensen ,&nbsp;Kymberle L. Sterling ,&nbsp;Andrea C. Villanti","doi":"10.1016/j.drugalcdep.2025.113019","DOIUrl":"10.1016/j.drugalcdep.2025.113019","url":null,"abstract":"<div><h3>Introduction</h3><div>Blunts (cigars with tobacco replaced or mixed with cannabis) incur health risks from exposure to tobacco and cannabis and are disproportionately used by young adults, people identifying as Black/African American (B/AA), people with lower socioeconomic status (SES), and people with mental health issues. This study described patterns of blunt use among US adults with multiple identities or circumstances increasing risk for blunt use.</div></div><div><h3>Methods</h3><div>We used Wave 6 (2021) (US adults; N = 30,516) of the Population Assessment of Tobacco and Health Study to examine the association between current blunt use and race (B/AA vs. non-B/AA) +  mental health (symptoms of internalizing/externalizing conditions) and socioeconomic status (SES; receipt of government assistance) using weighted multivariable logistic regression models, stratified by age (young adults [YAs] 18–34 vs. adults 35 + years).</div></div><div><h3>Results</h3><div>In 2021, 8.4 % of YAs and 1.4 % of adults 35 +  currently used blunts. Compared to people with joint advantage (e.g., non-B/AA + high SES), those identifying as B/AA with low SES (aOR=5.10, 95 % CI=4.16–6.26), high internalizing (aOR=4.83, 95 % CI=3.70–6.32), or externalizing conditions (aOR=4.74, 95 % CI=3.47–6.48) had greater odds of using blunts. The magnitude of the association between identifying as B/AA and having low SES (alone and jointly) and blunt use was greater among adults 35 +  years (vs. YAs).</div></div><div><h3>Conclusions</h3><div>Blunt use was most prevalent among B/AA adults with low SES or those who experienced mental health conditions. The magnitude of some inequities was greater among adults 35 + . Social and structural interventions to reduce blunt use among US adults could improve health equity.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"279 ","pages":"Article 113019"},"PeriodicalIF":3.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Driving after cannabis consumption among US adults ages 50 years and older: A short communication","authors":"Erin E. Bonar ,&nbsp;Lianlian Lei ,&nbsp;Matthias Kirch ,&nbsp;Kristen P. Hassett ,&nbsp;Erica Solway ,&nbsp;Dianne C. Singer ,&nbsp;Sydney N. Strunk ,&nbsp;J. Scott Roberts ,&nbsp;Preeti N. Malani ,&nbsp;Jeffrey T. Kullgren","doi":"10.1016/j.drugalcdep.2025.112985","DOIUrl":"10.1016/j.drugalcdep.2025.112985","url":null,"abstract":"<div><h3>Introduction</h3><div>Adults’ cannabis consumption is increasing in the United States (US) and consumption can increase risks such as impaired driving. Understanding driving after cannabis use (DCU) can guide lifespan-tailored prevention efforts. We evaluated the prevalence and correlates of self-reported DCU among cannabis-using adults ages 50 + .</div></div><div><h3>Methods</h3><div>Data are from a nationally representative study of adults ages 50 + (<em>N<strong>=</strong></em>3379); we included the sub-sample who self-reported past-year cannabis use (<em>N</em> = 729, 21.4 %). We measured socio-demographics, social functioning, caregiving, cannabis use, and motives for cannabis use and used unadjusted and adjusted logistic regression models to evaluate the associations of these factors with past-year DCU within 2<!--> <!-->h of consumption (yes/no).</div></div><div><h3>Results</h3><div>Sample socio-demographics included: 64.8 % age 50–64, 35.2 % age 65 + ; 50.5 % female; 71.8 % White Non-Hispanic, 10.5 % Black Non-Hispanic, 11.3 % Hispanic and 6.5 % other Non-Hispanic. There were 20.2 % (<em>n</em> = 142) who reported DCU. In unadjusted analyses, more frequent cannabis use and cannabis use motives for mental health and sleep were significantly associated with DCU. In adjusted analyses, men (vs. women, OR = 1.72, 95 % CI = 1.03–3.01), daily cannabis use (vs. once/twice OR = 3.31, 95 % CI: 1.79–6.12] and mental health motives (OR = 1.93, 95 % CI: 1.13–3.30) were significant.</div></div><div><h3>Conclusions</h3><div>About 1 in 5 adults ages 50 +  who use cannabis report DCU. Interventions to prevent cannabis-impaired driving should be targeted to these aging adults; clinicians may tailor intervention delivery based on relevant risk factors (e.g., mental health concerns, daily use).</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"278 ","pages":"Article 112985"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of remote to hybrid methods on recruitment and retention rates in a smoking cessation trial","authors":"Elizabeth S. Hawes ,&nbsp;Andrew P. Bontemps ,&nbsp;William P. Wagner ,&nbsp;Peter S. Hendricks ,&nbsp;Adrienne C. Lahti ,&nbsp;Andres Azuero ,&nbsp;Karen L. Cropsey","doi":"10.1016/j.drugalcdep.2025.112976","DOIUrl":"10.1016/j.drugalcdep.2025.112976","url":null,"abstract":"<div><h3>Objectives</h3><div>Due to the COVD-19 pandemic, many ongoing clinical trials had to rapidly shift to using remote trials, including our smoking cessation trial within a criminal legal population. The objective of this study was to compare recruitment rate, study adherence, retention, nicotine replacement therapy adherence, and quit attempts between participants who completed the study as planned (In-Person; N = 236), after implementation of a voucher system and additional check-in appointments (Incentivized; N = 126), and after the pandemic began (Hybrid; N = 153).</div></div><div><h3>Methods</h3><div>515 participants were recruited with criminal legal involvement from Birmingham, AL, and randomized to an In Vivo nicotine replacement therapy (NRT) sampling group or a standard smoking cessation counseling group, with both groups receiving 12 weeks of NRT.</div></div><div><h3>Results</h3><div>There were no significant differences in any of the study outcomes between the methodology groups, suggesting that hybrid methods of research do not result in a slower recruitment pace, less visits attended, or a higher likelihood of drop-out. Completing the study remotely did not appear to impact study outcomes such as likelihood of making a quit attempt or using NRT.</div></div><div><h3>Conclusions</h3><div>This study suggests that remote methods may be as effective as in-person methods in a clinical trial, although a randomized trial of these methods is needed.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"278 ","pages":"Article 112976"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}